Frontiers in Immunology (Dec 2023)

Case Report: Long-term metabolic response of metastatic uveal melanoma to pembrolizumab on FDG-PET/CT despite a serial pseudoprogressions phenomenon

  • Karim Amrane,
  • Karim Amrane,
  • Coline Le Meur,
  • Philippe Thuillier,
  • Philippe Thuillier,
  • Jacques Dzuko Kamga,
  • Pierre Alemany,
  • Frederic Chauvelot,
  • Clémence Niel,
  • Alex Bellange,
  • Ronan Abgral,
  • Ronan Abgral

DOI
https://doi.org/10.3389/fimmu.2023.1243208
Journal volume & issue
Vol. 14

Abstract

Read online

Uveal melanoma (UV) is a rare and aggressive melanoma with poor 1-year survival. up to 50% of UV patients develop metastases, mainly to the liver. Here, the authors present a 2-deoxy-2-[18F] fluoro-D-glucose positron emission tomography (18F-FDG-PET) study of a very rare case of secondarily metastatic UV in an 81-year-old Caucasian with a dramatic response to pembrolizumab associated with serial pseudogression. 18F-FDG-PET associated with clinical status and peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) were performed to guide therapeutic strategy due to an atypical pseudoprogression phenomenon.

Keywords